Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
NCT ID: NCT01968954
Last Updated: 2017-05-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
711 participants
INTERVENTIONAL
2013-10-31
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
NCT01968967
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
NCT02100514
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
NCT02135029
Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia
NCT02458287
Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects
NCT02947334
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bococizumab (PF-04950615;RN316)
Bococizumab (PF-04950615;RN316)
150 mg every 2 weeks, subcutaneous injection, 12 months
Placebo
Placebo
subcutaneous injection, every 2 weeks for 12 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bococizumab (PF-04950615;RN316)
150 mg every 2 weeks, subcutaneous injection, 12 months
Placebo
subcutaneous injection, every 2 weeks for 12 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fasting LDL-C \> 70 mg/dL and triglyceride \<=400 mg/dL.
* High or very high risk of incurring a cardiovascular event.
Exclusion Criteria
* Cardiovascular or cerebrovascular event of procedures during the past 30 days.
* Congestive heart failure NYHA class IV.
* Poorly controlled hypertension.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Achieve Clinical Research, LLC
Birmingham, Alabama, United States
Cardiovascular Associates of the Southeast, LLC
Birmingham, Alabama, United States
Southwest Heart Group
Tucson, Arizona, United States
ARA-Arizona Research Associates
Tucson, Arizona, United States
Diagnamics, Inc.
Encinitas, California, United States
Encompass Clinical Research North Coast
Encinitas, California, United States
MD Studies, Inc.
Fountain Valley, California, United States
Alliance Research Centers
Laguna Hills, California, United States
Prime Care Clinical Research
Laguna Hills, California, United States
Providence Clinical Research
North Hollywood, California, United States
San Diego Family Care
San Diego, California, United States
St. Joseph's Medical Associates
Stockton, California, United States
Orange County Research Center
Tustin, California, United States
Clinical Research Advantage, Inc./Cassidy Medical Group - Vista
Vista, California, United States
Elite Clinical Trials
Wildomar, California, United States
Expresscare Clinical Research
Colorado Springs, Colorado, United States
Soundview Medical Associates
Norwalk, Connecticut, United States
Eastern Research, Inc.
Hialeah, Florida, United States
East Coast Institute for Research, LLC at Northeast Florida Endocrine & Diabetes Associates
Jacksonville, Florida, United States
Care Partners Clinical Research, LLC
Jacksonville, Florida, United States
Prestige Clinical Research Center Inc
Miami, Florida, United States
Edgewater Medical Research
New Smyrna Beach, Florida, United States
Gulfcoast Medical Research Center, LLC
Tampa, Florida, United States
Fellows Research Alliance, Inc.
Savannah, Georgia, United States
SouthCoast Medical Group
Savannah, Georgia, United States
Evanston Premier Healthcare Research LLC
Evanston, Illinois, United States
Comunity Clinical Research Center
Anderson, Indiana, United States
American Health Network of Indiana, LLC
Avon, Indiana, United States
Midwest Institute for Clinical Research
Indianapolis, Indiana, United States
Horizon Research Group of Opelousas, LLC
Eunice, Louisiana, United States
Internal Medicine Associates
Eunice, Louisiana, United States
Beacon Clinical Research, LLC
Quincy, Massachusetts, United States
Allina Health System, dba Abbott Northwestern Hospital
Minneapolis, Minnesota, United States
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States
University of MN, Lillehei Clinical Trials Unit
Minneapolis, Minnesota, United States
Montana Medical Research Inc.
Missoula, Montana, United States
PMG Research of Raleigh, LLC d/b/a PMG Research of Cary
Cary, North Carolina, United States
Clinical Trials of America, Inc.
Winston-Salem, North Carolina, United States
Radiant Research, Inc
Akron, Ohio, United States
Rapid Medical Research, Inc.
Cleveland, Ohio, United States
The Office of Daniel G. Williams, MD
Perrysburg, Ohio, United States
Great Lakes Medical Research, LLC
Willoughby, Ohio, United States
South Oklahoma Heart Research LLC
Oklahoma City, Oklahoma, United States
Integrated Medical Research, PC
Ashland, Oregon, United States
Columbia Research Group, Inc.
Portland, Oregon, United States
Harleysville Medical Associates
Harleysville, Pennsylvania, United States
Perelman Center for Advanced Medicine Heart & Vascular Center
Philadelphia, Pennsylvania, United States
Berks Cardiologists, Ltd.
Wyomissing, Pennsylvania, United States
Medical Research South,LLC
Charleston, South Carolina, United States
Berkeley Family Practice
Moncks Corner, South Carolina, United States
Internal Medicine and Pediatric Associates of Bristol, PC
Bristol, Tennessee, United States
3 rd Coast Research Associates
Corpus Christi, Texas, United States
Texas Center For Drug Development, Inc.
Houston, Texas, United States
Pioneer Research Solutions, Inc.
Houston, Texas, United States
Protenium Clinical Research
Hurst, Texas, United States
Utah Cardiology, P.C.
Layton, Utah, United States
National Clinical Research - Norfolk, Inc.
Norfolk, Virginia, United States
Premier Clinical Research
Spokane, Washington, United States
Australian Clinical Research Network
Maroubra, New South Wales, Australia
Core Research Group Pty Ltd
Milton, Queensland, Australia
The Avenue Cardiovascular Centre
St Kilda East, Victoria, Australia
Ecogene-21
Chicoutimi, Quebec, Canada
Montreal Heart Institute
Montreal, Quebec, Canada
Diex Research Montreal Inc.
Montreal, Quebec, Canada
ALPHA Recherche Clinique
Québec, Quebec, Canada
Centre Hospitalier Universitaire de Sherbrooke (CHUS)
Sherbrooke, Quebec, Canada
Medexa Recherche
Victoriaville, Quebec, Canada
Fakultni nemocnice Hradec Kralove
Hradec Králové, , Czechia
Kardiologie a interni lekarstvi
Prague, , Czechia
Lekarsky dum Ormiga
Zlín, , Czechia
Klinische Forschung Berlin-Mitte GmbH
Berlin, , Germany
Klinische Forschung Hannover - Mitte GmbH
Hanover, , Germany
Klinikum der Stadt Ludwigshafen am Rhein gGmbH
Ludwigshafen, , Germany
Klinische Forschung Schwerin GmbH
Schwerin, , Germany
The Chinese University of Hong Kong
Shatin, , Hong Kong
Department of Medicine & Therapeutics-The Chinese University of Hong Kong
Shatin, NT, , Hong Kong
IRCCS Ospedale San Raffaele
Milan, MI, Italy
IRCCS Centro Cardiologico Fondazione Monzino
Milan, MI, Italy
IRCCS Istituto Auxologico Italiano
Milan, MI, Italy
Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone"
Palermo, PA, Italy
Dipartimento di Medicina Interna e Specialita Mediche Policlinico Umberto I
Roma, RM, Italy
SYNEXUS Polska Sp. z o.o. Oddzial w Katowicach
Katowice, Masovian Voivodeship, Poland
NZOZ Terapia Optima
Katowice, Silesian Voivodeship, Poland
Synexus Polska Sp. z o.o. Oddzial w Gdyni
Gdynia, , Poland
Niepubliczny Zaklad Opieki Zdrowotnej CEREO-MED Sp. z o.o.
Lodz, , Poland
Medicus w Opolu Sp z o.o.
Opole, , Poland
Medicome Sp. z o.o.
Oświęcim, , Poland
Synexus Polska Sp. z o.o Oddzial w Poznaniu
Poznan, , Poland
Centrum Medyczne Ogrodowa Sp. z o.o.
Skierniewice, , Poland
Centrum Medyczne "SOPMED" Sp. z o.o.
Sopot, , Poland
Synexus Polska Sp. z o.o. Oddzial w Warszawie
Warsaw, , Poland
Centrum Medyczne AMED
Warsaw, , Poland
CSK MSW w Warszawie, Klinika Kardiologii Zachowawczej i Nadcisnienia Tetniczego
Warsaw, , Poland
Synexus Polska Sp. z o.o. Oddzial we Wroclawiu
Wroclaw, , Poland
The Catholic University of Korea, Uijeongbu St. Mary's Hospital
Uijeongbu-si, Gyeonggi-do, South Korea
Yonsei University Wonju Severance Christian Hospital
Gangwon-Do, , South Korea
Chonnam National University Hospital
Gwangju, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Gangnam Sevrance Hospital, Yeonsei University Health System
Seoul, , South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, , South Korea
Ajou University Hospital
Suwon, , South Korea
Ulsan University Hospital
Ulsan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wang EQ, Kaila N, Plowchalk D, Gibiansky L, Yunis C, Sweeney K. Population PK/PD modeling of low-density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti-PCSK9 monoclonal antibody. CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):2013-2026. doi: 10.1002/psp4.13050. Epub 2023 Nov 22.
McCush F, Wang E, Yunis C, Schwartz P, Baltrukonis D. Anti-drug Antibody Magnitude and Clinical Relevance Using Signal to Noise (S/N): Bococizumab Case Study. AAPS J. 2023 Sep 2;25(5):85. doi: 10.1208/s12248-023-00846-x.
Chasman DI, Hyde CL, Giulianini F, Danning RD, Wang EQ, Hickling T, Ridker PM, Loomis AK. Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1. Sci Rep. 2022 Mar 11;12(1):4266. doi: 10.1038/s41598-022-07997-5.
Wang EQ, Bukowski JF, Yunis C, Shear CL, Ridker PM, Schwartz PF, Baltrukonis D. Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies. BioDrugs. 2019 Oct;33(5):571-579. doi: 10.1007/s40259-019-00375-0.
Ridker PM, Rose LM, Kastelein JJP, Santos RD, Wei C, Revkin J, Yunis C, Tardif JC, Shear CL; Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. J Clin Lipidol. 2018 Jul-Aug;12(4):958-965. doi: 10.1016/j.jacl.2018.03.088. Epub 2018 Apr 3.
Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C; SPIRE Investigators. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med. 2017 Apr 20;376(16):1517-1526. doi: 10.1056/NEJMoa1614062. Epub 2017 Mar 17.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-002642-37
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
SPIRE-HR
Identifier Type: OTHER
Identifier Source: secondary_id
B1481019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.